Metabolomic profile of cancer stem cell-derived exosomes from patients with malignant melanoma
Metadatos
Mostrar el registro completo del ítemAutor
Palacios Ferrer, José Luis; García Ortega, María Belén; García Chaves, María Ángel; Díaz, Caridad; Boulaiz Tassi, Houria; Valdivia, Javier; Jurado, José Miguel; Almazán Fernández, Francisco Manuel; Arias Santiago, Salvador; Amezcua, Víctor; Peinado, Héctor; Vicente, Francisca; Pérez del Palacio, José; Marchal Corrales, Juan AntonioEditorial
Wiley
Materia
Biomarkers Cancer stem cells Exosomes Malignant melanoma Metabolomics
Fecha
2020-11Referencia bibliográfica
Palacios‐Ferrer, J. L., García‐Ortega, M. B., Gallardo‐Gómez, M., García, M. Á., Díaz, C., Boulaiz, H., ... & Marchal, J. A. (2020). Metabolomic profile of cancer stem cell‐derived exosomes from patients with malignant melanoma. Molecular Oncology. [doi:10.1002/1878-0261.12823]
Patrocinador
MICIU FPU15/03682 FPU15/02350; Ministerio de Ciencia, Innovación y Universidades (MICIU) MAT2015-62644.C2.2.R RTI2018-101309-BC2; Instituto de Salud Carlos III PIE16-00045; Junta de Andalucía SOMM17/6109/UGR (UCE-PP2017-3); European Union (EU) SOMM17/6109/UGR (UCE-PP2017-3); Chair 'Doctors Galera-Requena in cancer stem cell research' CMC-CTS963; Fundación MEDINAResumen
Malignant melanoma (MM) is the most aggressive and life-threatening
form of skin cancer. It is characterized by an extraordinary metastasis
capacity and chemotherapy resistance, mainly due to melanoma cancer
stem cells (CSCs). To date, there are no suitable clinical diagnostic, prognostic
or predictive biomarkers for this neoplasia. Therefore, there is an
urgent need for new MM biomarkers that enable early diagnosis and effective
disease monitoring. Exosomes represent a novel source of biomarkers
since they can be easily isolated from different body fluids. In this work, a
primary patient-derived MM cell line enriched in CSCs was characterized
by assessing the expression of specific markers and their stem-like properties.
Exosomes derived from CSCs and serums from patients with MM
were characterized, and their metabolomic profile was analysed by highresolution
mass spectrometry (HRMS) following an untargeted approach
and applying univariate and multivariate statistical analyses. The aim of
this study was to search potential biomarkers for the diagnosis of this disease.
Our results showed significant metabolomic differences in exosomes
derived from MM CSCs compared with those from differentiated tumour
cells and also in serum-derived exosomes from patients with MM compared
to those from healthy controls. Interestingly, we identified similarities between structural lipids differentially expressed in CSC-derived exosomes
and those derived from patients with MM such as the glycerophosphocholine
PC 16:0/0:0. To our knowledge, this is the first metabolomic-based
study aimed at characterizing exosomes derived from melanoma CSCs and
patients’ serum in order to identify potential biomarkers for MM diagnosis.
We conclude that metabolomic characterization of CSC-derived exosomes
sets an open door to the discovery of clinically useful biomarkers in
this neoplasia.